Maximilian Wiesenfarth

Ulm, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Blood SOD1 Activity in ALS Patients Receiving Tofersen Treatment.

Blood SOD1 Activity in ALS Patients Receiving Tofersen Treatment.

Journal: Annals of neurology

Published: April 22, 2026

Feasibility and Tolerability of Ketogenic Interventions in Amyotrophic Lateral Sclerosis-A Dose-Finding Case Series.

Feasibility and Tolerability of Ketogenic Interventions in Amyotrophic Lateral Sclerosis-A Dose-Finding Case Series.

Journal: Nutrients

Published: March 25, 2026

Evaluating the short-term and long-term therapeutic effects of immunoadsorption compared with plasma exchange in chronic inflammatory demyelinating polyneuropathy: a long-term, prospective, observational study.

Evaluating the short-term and long-term therapeutic effects of immunoadsorption compared with plasma exchange in chronic inflammatory demyelinating polyneuropathy: a long-term, prospective, observational study.

Journal: EClinicalMedicine

Published: September 18, 2025

Disruption of the angiopoietin-like system connects lipid homeostasis and hypothalamic dysfunction in ALS.

Disruption of the angiopoietin-like system connects lipid homeostasis and hypothalamic dysfunction in ALS.

Journal: BMC medicine

Published: July 24, 2025

Neurofilament light chain reference values in serum and cerebrospinal fluid: a bi-compartmental analysis in neurological diseases.

Neurofilament light chain reference values in serum and cerebrospinal fluid: a bi-compartmental analysis in neurological diseases.

Journal: Journal of neurology

Published: June 01, 2025

CSF levels of the somatodendritic protein MAP2 are increased in ALS and predict shorter survival.

CSF levels of the somatodendritic protein MAP2 are increased in ALS and predict shorter survival.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: March 10, 2025

Correction: Clinical characterization of common pathogenic variants of SOD1-ALS in Germany.

Correction: Clinical characterization of common pathogenic variants of SOD1-ALS in Germany.

Journal: Journal of neurology

Published: March 08, 2025

Comparative analysis of cerebrospinal fluid neurofilament medium, light and heavy chain in neurodegenerative diseases using an in-house assay for the detection of neurofilament medium chain.

Comparative analysis of cerebrospinal fluid neurofilament medium, light and heavy chain in neurodegenerative diseases using an in-house assay for the detection of neurofilament medium chain.

Journal: EBioMedicine

Published: March 08, 2025

Peptidomic analysis of CSF reveals new biomarker candidates for amyotrophic lateral sclerosis.

Peptidomic analysis of CSF reveals new biomarker candidates for amyotrophic lateral sclerosis.

Journal: EMBO molecular medicine

Published: February 04, 2025

Targeted Proteomics upon Treatment with Tofersen Identifies Novel Response Markers for Superoxide Dismutase 1-Linked Amyotrophic Lateral Sclerosis.

Targeted Proteomics upon Treatment with Tofersen Identifies Novel Response Markers for Superoxide Dismutase 1-Linked Amyotrophic Lateral Sclerosis.

Journal: Annals of neurology

Published: December 16, 2024

Population-Based Versus Hospital-Based Data in Amyotrophic Lateral Sclerosis-A Factor to Consider?

Population-Based Versus Hospital-Based Data in Amyotrophic Lateral Sclerosis-A Factor to Consider?

Journal: European journal of neurology

Published: October 18, 2024

Tofersen and other antisense oligonucleotides in ALS.

Tofersen and other antisense oligonucleotides in ALS.

Journal: Therapeutic advances in neurological disorders

Published: September 16, 2024

Showing 1-12 of 19

Last Updated: 09/26/2026